| pubmed-article:3262566 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3262566 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:3262566 | lifeskim:mentions | umls-concept:C0009402 | lld:lifeskim |
| pubmed-article:3262566 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:3262566 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:3262566 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:3262566 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:3262566 | lifeskim:mentions | umls-concept:C0279218 | lld:lifeskim |
| pubmed-article:3262566 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:3262566 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:3262566 | pubmed:dateCreated | 1988-11-23 | lld:pubmed |
| pubmed-article:3262566 | pubmed:abstractText | Ten patients with metastatic colorectal carcinoma were treated with MAb 17-1A (IgG2A). Before infusion, MAb was incubated in vitro with isolated autologous blood mononuclear cells. Treatment was given in repeated courses (2-4 times) to a maximum dose of 1000 mg of MAb 17-1A. One patient achieved a clinical complete remission, two patients had a minor response and one patient had stable disease for 5 months. The median survival for the four responders was 19 months compared to 7 months for the six non-responders. Therapy was well tolerated. In this series, 32 infusions of MAb 17-1A were given. The serum half-life of MAb 17-1A was approximately 22 hours. All patients developed anti-mouse antibodies of both IgG and IgM classes. No relation between adverse reactions and anti-mouse antibodies was seen. At 3 occasions allergic reactions were noted. Skin test with MAb 17-1A seems to reliably predict for allergic reactions. | lld:pubmed |
| pubmed-article:3262566 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3262566 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3262566 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3262566 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3262566 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3262566 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3262566 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3262566 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:3262566 | pubmed:issn | 0272-457X | lld:pubmed |
| pubmed-article:3262566 | pubmed:author | pubmed-author:BiberfeldPP | lld:pubmed |
| pubmed-article:3262566 | pubmed:author | pubmed-author:WahrenBB | lld:pubmed |
| pubmed-article:3262566 | pubmed:author | pubmed-author:MellstedtHH | lld:pubmed |
| pubmed-article:3262566 | pubmed:author | pubmed-author:LefvertA KAK | lld:pubmed |
| pubmed-article:3262566 | pubmed:author | pubmed-author:RiegerAA | lld:pubmed |
| pubmed-article:3262566 | pubmed:author | pubmed-author:ChristenssonB... | lld:pubmed |
| pubmed-article:3262566 | pubmed:author | pubmed-author:FrödinJ EJE | lld:pubmed |
| pubmed-article:3262566 | pubmed:author | pubmed-author:HarmenbergUU | lld:pubmed |
| pubmed-article:3262566 | pubmed:author | pubmed-author:ShetyeJJ | lld:pubmed |
| pubmed-article:3262566 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3262566 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:3262566 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3262566 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3262566 | pubmed:pagination | 309-21 | lld:pubmed |
| pubmed-article:3262566 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:meshHeading | pubmed-meshheading:3262566-... | lld:pubmed |
| pubmed-article:3262566 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3262566 | pubmed:articleTitle | Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas. | lld:pubmed |
| pubmed-article:3262566 | pubmed:affiliation | Department of Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden. | lld:pubmed |
| pubmed-article:3262566 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3262566 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3262566 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3262566 | lld:pubmed |
